Comparison of testing and validation cohort
| . | Testing, n = 80 . | Validation, n = 30 . | P . |
|---|---|---|---|
| Initial presentation | |||
| Female, n (%) | 50 (63) | 17 (57) | .66 |
| PVT, n (%) | 52 (65) | 25 (83) | .07 |
| Age at diagnosis, mean (range), y | 42 (17-73) | 47 (7-76) | .16 |
| Hemoglobin, median (range), g/dL* | 14.2 (8.6-19.5) | 13 (9.2-21.6) | .94 |
| Platelet count, median (range), ×109/L* | 340 (136-2103) | 339 (156-1700) | .82 |
| WBC count, median (range), ×109/L* | 8.6 (3.5-34.9) | 8 (3-14) | .42 |
| Spleen size BCM, median (range), cm† | 2 (0-9) | 1.5 (0-10) | .76 |
| MPN subtype and driver mutation, n (%) | |||
| PV | 52 (65) | 12 (40) | .04 |
| ET | 23 (29) | 13 (43) | .04 |
| PMF | 5 (6) | 5 (17) | .04 |
| JAK2 V617F/CALR/MPL, n | 76/4/0 | 29/0/1 | .20 |
| JAK2 allele burden, median (range), % | 14.5 (0.4-93) | 30 (4-99) | .33 |
| JAK2 allele burden ≥50%, n (%) | 16 (21) | 4 (13) | .58 |
| Additional mutation, n (%) | 37 (46) | 9 (30) | .14 |
| High-risk score, n (%) | 23 (29) | 8 (27) | 1.00 |
| Treatment and outcomes | |||
| Follow-up, median (range), y | 11 (0.3-37) | 7 (0.3-39) | .34 |
| Cytoreductive treatment, n (%) | 75 (94) | 30 (100) | .32 |
| Primary outcomes, n (%) | 10 (13) | 9 (30) | .05 |
| Secondary myelofibrosis | 7 (9) | 7 (28) | .04 |
| Acute leukemia | 2 (3) | 2 (7) | .30 |
| Death | 5 (6) | 4 (13)‡ | .25 |
| Thrombosis, n (%) | |||
| Thrombophilia | 14 (18) | 3 (10) | .39 |
| Anticoagulant therapy | 78 (97) | 27 (90) | .13 |
| Thrombosis recurrence | 12 (15) | 8 (27) | .17 |
| . | Testing, n = 80 . | Validation, n = 30 . | P . |
|---|---|---|---|
| Initial presentation | |||
| Female, n (%) | 50 (63) | 17 (57) | .66 |
| PVT, n (%) | 52 (65) | 25 (83) | .07 |
| Age at diagnosis, mean (range), y | 42 (17-73) | 47 (7-76) | .16 |
| Hemoglobin, median (range), g/dL* | 14.2 (8.6-19.5) | 13 (9.2-21.6) | .94 |
| Platelet count, median (range), ×109/L* | 340 (136-2103) | 339 (156-1700) | .82 |
| WBC count, median (range), ×109/L* | 8.6 (3.5-34.9) | 8 (3-14) | .42 |
| Spleen size BCM, median (range), cm† | 2 (0-9) | 1.5 (0-10) | .76 |
| MPN subtype and driver mutation, n (%) | |||
| PV | 52 (65) | 12 (40) | .04 |
| ET | 23 (29) | 13 (43) | .04 |
| PMF | 5 (6) | 5 (17) | .04 |
| JAK2 V617F/CALR/MPL, n | 76/4/0 | 29/0/1 | .20 |
| JAK2 allele burden, median (range), % | 14.5 (0.4-93) | 30 (4-99) | .33 |
| JAK2 allele burden ≥50%, n (%) | 16 (21) | 4 (13) | .58 |
| Additional mutation, n (%) | 37 (46) | 9 (30) | .14 |
| High-risk score, n (%) | 23 (29) | 8 (27) | 1.00 |
| Treatment and outcomes | |||
| Follow-up, median (range), y | 11 (0.3-37) | 7 (0.3-39) | .34 |
| Cytoreductive treatment, n (%) | 75 (94) | 30 (100) | .32 |
| Primary outcomes, n (%) | 10 (13) | 9 (30) | .05 |
| Secondary myelofibrosis | 7 (9) | 7 (28) | .04 |
| Acute leukemia | 2 (3) | 2 (7) | .30 |
| Death | 5 (6) | 4 (13)‡ | .25 |
| Thrombosis, n (%) | |||
| Thrombophilia | 14 (18) | 3 (10) | .39 |
| Anticoagulant therapy | 78 (97) | 27 (90) | .13 |
| Thrombosis recurrence | 12 (15) | 8 (27) | .17 |
Missing data for 8 and 6 patients in initial and validation cohort, respectively.
Missing data for 16 and 7 patients in initial and validation cohort, respectively.
Death related to refractory acute leukemia (n = 2), nonrelapse mortality after allogeneic hematopoietic stem cell transplantation (n = 1), and sudden cardiac arrest (n = 1).